Status Change

Hutchmed advances HMPL-760 PK study to active phase in China

A 24-subject Phase 1 study testing how food and a proton pump inhibitor affect HMPL-760 absorption has moved to active status, with data due around October 2026.

By AppliedXLJuly 13, 2026Trial NCT07643272

Executive Summary

Hutchmed's food-effect and drug-interaction study of HMPL-760 has moved into its active treatment phase after completing enrollment on schedule.
The study measures how a meal and a proton pump inhibitor change the body's absorption of HMPL-760, information that will inform dosing guidance rather than efficacy.
HMPL-760's target and mechanism are not shared by any other trial in the healthy-volunteer pharmacokinetic field surveyed, leaving this readout isolated from a direct competitive comparison.
The trial's primary completion date has held steady since it was first posted, and the pharmacokinetic data due around that date will shape how HMPL-760 is dosed relative to food and gastric-acid-suppressing co-medications going forward.

The status change

NCT07643272 shifted from Not yet recruiting to Active, not recruiting on July 13, 2026, according to the registry's own status update. The trial had been first posted on June 11, 2026, with a start date that later firmed from June 1 to June 30, 2026, and enrollment type updated from Anticipated to Actual at the full target of 24 subjects. That progression, first posting to enrollment completion to active dosing within about five weeks, is a routine early-phase execution pattern, not an operational flag. A+1

What the trial tests

The study is designed to measure how food and a proton pump inhibitor (acid-reducing stomach medication) affect the pharmacokinetics of HMPL-760 capsules, a small-molecule drug administered orally. Its primary endpoints are AUC 0-inf and AUC 0-last (total drug exposure over time) and Cmax (peak plasma concentration), each measured from Day 1 through Day 25. Four treatment arms compare fasted dosing, a high-fat meal, a low-fat meal, and co-administration with rabeprazole 20 mg, an acid-reducing drug given daily from Day 15 through Day 21 before a concomitant HMPL-760 dose on Day 21. Secondary endpoints track adverse events, lab abnormalities, time to peak concentration, half-life, and lag time through Day 32. NCT07643272

The competitive frame

HMPL-760's target is not characterized in the trials surveyed, so this study cannot be placed against a direct mechanism comparator. Among Phase 1 and Phase 2 pharmacokinetic and safety studies run in healthy volunteers by other sponsors, including NewAmsterdam Pharma's obicetrapib, ViiV Healthcare's dezecapavir, and AbbVie's emraclidine, none share HMPL-760's target, leaving the study without a same-mechanism peer. That isolation reflects the study's narrow purpose: characterizing absorption behavior for a single asset, not testing a mechanism against rivals.

Sponsor track record

Hutchmed has completed 74 of 86 trials tracked, an 86% completion rate, with 13 trials terminated across its broader portfolio. That base rate provides context for execution risk generally, though this single pharmacokinetic study carries none of the enrollment or protocol instability signals, such as repeated amendments or timeline slippage, that would elevate concern on its own. The study's registry-churn proxy shows zero amendments beyond the single status update, a stable read. NCT07643272

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.